Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart
  • Log out

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions

Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension

A. Lavelle, R. Sugrue, G. Lawler, N. Mulligan, B. Kelleher, D. M. Murphy, S. P. Gaine
European Respiratory Journal 2009 34: 770-771; DOI: 10.1183/09031936.00058409
A. Lavelle
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Sugrue
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. Lawler
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
N. Mulligan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
B. Kelleher
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. M. Murphy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. P. Gaine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

To the Editor:

Sitaxentan sodium is an endothelin receptor antagonist (ERA) recently approved for the management of pulmonary arterial hypertension (PAH) 1. While hepatotoxicity is a recognised side-effect of treatment with the ERA bosentan, it is considered to be less common with sitaxentan 2–4. We recently admitted two patients with severe hepatotoxicity on sitaxentan to the Pulmonary Hypertension Unit at the Mater Misericordiae University Hospital (Dublin, Ireland).

The first patient was a 47-yr-old male with PAH associated with congenital heart disease. He had a past history of ventricular septal defect closure at 12 yrs of age and was referred to our service with a history of gradual diminishing exercise capacity. His right heart catherisation demonstrated a pulmonary artery systolic pressure of 80 mmHg and a normal pulmonary capillary wedge pressure. He was commenced on sitaxentan 100 mg q.d. Initial liver function tests (LFTs) were normal, and the patient continued to undergo monthly LFT monitoring. At 3 months, he was experiencing an improvement in his symptoms and 6-min walking distance. However, 1 month later, he became generally unwell, with nausea, vomitting, anorexia and weight loss. He denied abdominal pain or pruritis. Physical examination was notable for icterus without evidence of hepatomegaly. The course of the patient’s LFTs are shown in figure 1a⇓. Treatment with sitaxentan was immediately discontinued. The patient was on no other hepatotoxic medications. At review 2 weeks later, his clinical condition was unchanged and LFTs had deteriorated; he was admitted to the hospital. Initial haematological tests showed a haemoglobin level of 15.7 g·dL−1, a white cell count of 6.54 ×109·L−1, a platelet count of 158×109·L−1, erythrocyte sedimentation rate 2 mm in the first hour, a C-reactive protein level of 5.8 g·L−1, and normal renal function tests. Auto-antibody screening was negative apart from parietal cell antibody positivity. α1-Antitrypsin and copper levels were within normal limits. Virology serology, including hepatitis A, B and C, HIV and anti-cytomegalovirus were all negative. Epstein–Barr virus-associated nuclear antigen immunoglobulin G was positive, indicating previous exposure. The patient was commenced on vitamin K for his coagulopathy; however, his INR still peaked at 1.6. Liver ultrasound showed a normal liver in both size and echogenecity, with no evidence of intrahepatic or common bile duct dilation. The portal vein was patent. As part of diagnostic investigations, the patient underwent transjugular liver biopsy. This was consistent with severe acute drug-induced liver injury (fig. 2⇓). Ursodeoxycholic acid was commenced. The patient’s clinical condition and liver function testing gradually improved over the following months (fig. 1a⇓).

Fig. 1—
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1—

Change in liver function tests over time from commencement of sitaxentan therapy in months in the a) first and b) second patients. The courses of bilirubin (▵), aspartate aminotransferase (⋄) and alanine aminotransferase (□) are shown. The arrows mark the beginning and end of sitaxentan therapy.

Fig. 2—
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 2—

Liver biopsy of patient 1 demonstrating typical features of a drug reaction i.e. ballooning degeneration of hepatocytes, bile stasis and infiltration by eosinophils. Haematoxylin and eosin staining. Scale bar = 2 μm.

The second patient was a 70-yr-old female with severe idiopathic PAH. She was commenced on sitaxentan 100 mg a day at the end of July 2008, with monthly LFT monitoring. At the time that sitaxentan was commenced, she was also taking aspirin 75 mg a day and the antihypertensives doxazosin XL 8 mg and valsartan/hydrochlorothiazide 80/12.5 mg once a day. Frusemide 20 mg a day commenced shortly after the ERA was initiated. However, after 3 months, the patient’s LFTs increased and continued despite discontinuing the sitaxsentan in mid-November (fig. 1b⇑). The patient’s aspartate aminotransferase (AST) and alanine aminotransferase (ALT) peaked at 1,198 IU and 1,040 IU respectively, while her bilirubin peaked at 426 μmol·L−1, with her INR reaching 1.6 off anticoagulation. Two months after the drug was discontinued, the AST and ALT had returned to normal but the bilirubin remained >200 umol·L−1. Both hepatitis B surface antigen and hepatitis C virus were negative; however, as in the first case, the patient’s parietal cell antibody was positive. Her liver ultrasound revealed a normal liver size and echogenecity. A liver biopsy (fig. 3⇓) showed a moderate portal and parenchymal lymphocytic infiltrate with scattered eosinophils and extensive active hepatocyte injury. Areas of confluent necrosis were identified. Although the patient recovered from the acute liver injury, she was readmitted in January 2009 with lobar pneumonia and persistant jaundice, and died of respiratory failure.

Fig. 3—
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 3—

Liver biopsy of patient 2 showing moderate portal and parenchymal lymphocytic infiltrate with scaterred eosinophils and extensive active hepatocyte injury. Haematoxylin and eosin staining. Scale bar = 2 μm.

While initial studies with sitaxentan 300 mg demonstrated its potential to cause liver injury following the death of one patient 3, a follow-up study using sitaxentan at a lower dose of 100 mg q.d. caused no significant elevation of liver enzymes 5. However, an accumulation of sitaxentan may occur as a result of nonlinear pharmacokinetics previously demonstrated during drug development 3. Accumulation may explain the delay in time to injury and the prolonged recovery following discontinuation of the drug.

The liver injury suffered by the two patients presented in this study was severe. The transaminases peaking at >30 times the upper limit of normal. In addition, the pattern of hepatic injury was mixed with significant elevation of both bilirubin and alkaline phosphatase also observed. Both cases occurred within the first 12 weeks of treatment and resulted in a protracted period of jaundice.

In conclusion, we have presented two cases of fulminant hepatic failure from sitaxentan therapy for PAH. These cases emphasise the importance of monthly liver function testing in patients treated with these agents.

Statement of interest

A statement of interest for S.P. Gaine can be found at www.erj.ersjournals.com/misc/statements.dtl

Footnotes

  • For editorial comments see page 529.

    • © ERS Journals Ltd

    References

    1. ↵
      O'Callaghan DS, Gaine SP. Sitaxsentan: an endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension. Int J Clin Pract 2006;60:475–481.
      OpenUrlCrossRefPubMedWeb of Science
    2. ↵
      Benza RL, Mehta S, Keogh A, et al. Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan. J Heart Lung Transplant 2007;26:63–69.
      OpenUrlCrossRefPubMedWeb of Science
    3. ↵
      Barst RJ, Rich S, Widlitz A, et al. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. Chest 2002;121:1860–1868.
      OpenUrlCrossRefPubMedWeb of Science
    4. ↵
      Humbert M, Segal ES, Kiely DG, et al. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J 2007;30:338–344.
      OpenUrlAbstract/FREE Full Text
    5. ↵
      Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;169:441–447.
      OpenUrlCrossRefPubMedWeb of Science
    View Abstract
    PreviousNext
    Back to top
    View this article with LENS
    Vol 34 Issue 3 Table of Contents
    European Respiratory Journal: 34 (3)
    • Table of Contents
    • Index by author
    Email

    Thank you for your interest in spreading the word on European Respiratory Society .

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension
    (Your Name) has sent you a message from European Respiratory Society
    (Your Name) thought you would like to see the European Respiratory Society web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Print
    Citation Tools
    Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension
    A. Lavelle, R. Sugrue, G. Lawler, N. Mulligan, B. Kelleher, D. M. Murphy, S. P. Gaine
    European Respiratory Journal Sep 2009, 34 (3) 770-771; DOI: 10.1183/09031936.00058409

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero

    Share
    Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension
    A. Lavelle, R. Sugrue, G. Lawler, N. Mulligan, B. Kelleher, D. M. Murphy, S. P. Gaine
    European Respiratory Journal Sep 2009, 34 (3) 770-771; DOI: 10.1183/09031936.00058409
    Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo
    Full Text (PDF)

    Jump To

    • Article
      • Statement of interest
      • Footnotes
      • References
    • Figures & Data
    • Info & Metrics
    • PDF
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    More in this TOC Section

    • Obesity in COPD: the effect of water-based exercise
    • Burden of CAP in Italian general practice
    • Neutrophilia independently predicts death in tuberculosis
    Show more Letters

    Related Articles

    Navigate

    • Home
    • Current issue
    • Archive

    About the ERJ

    • Journal information
    • Editorial board
    • Press
    • Permissions and reprints
    • Advertising

    The European Respiratory Society

    • Society home
    • myERS
    • Privacy policy
    • Accessibility

    ERS publications

    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS books online
    • ERS Bookshop

    Help

    • Feedback

    For authors

    • Instructions for authors
    • Publication ethics and malpractice
    • Submit a manuscript

    For readers

    • Alerts
    • Subjects
    • Podcasts
    • RSS

    Subscriptions

    • Accessing the ERS publications

    Contact us

    European Respiratory Society
    442 Glossop Road
    Sheffield S10 2PX
    United Kingdom
    Tel: +44 114 2672860
    Email: journals@ersnet.org

    ISSN

    Print ISSN:  0903-1936
    Online ISSN: 1399-3003

    Copyright © 2023 by the European Respiratory Society